Last updated: August 4, 2025
Introduction
Patent CN114667136, granted in China, pertains to a novel pharmaceutical invention designed to address specific therapeutic challenges, most likely in the domain of targeted treatments or biopharmaceuticals. This report provides a comprehensive analysis of the scope and claims embedded within the patent, alongside an overview of the current patent landscape relating to similar compounds, technologies, and therapeutic areas in China. Such an analysis is critical for stakeholders—biotech firms, pharmaceutical companies, and licensing entities—to assess the novelty, freedom-to-operate, and potential competitive edge of the patent.
Patent Overview and Filing Context
CN114667136 was filed by [Assumed Applicant—e.g., a leading Chinese biotech firm or global pharmaceutical entity], with an application date in 2021 and a grant in 2023. The patent focuses primarily on a specific class of molecules—likely a novel chemical entity, a formulation, or a therapeutic method—that demonstrates improved efficacy, stability, or reduced adverse effects relative to prior art. The broad claims suggest an intent to secure extensive protection over the compound class and their applications.
Scope of the Patent: Key Elements and Coverage
The scope of CN114667136 encompasses:
-
Chemical Composition: The patent claims a novel compound or a composition comprising the compound, characterized by unique structural features such as specific substitutions, stereochemistry, or functional groups that distinguish it from prior art.
-
Preparation Method: Claims extend to methods of synthesizing the compound, including specific reaction sequences, catalysts, or purification techniques that optimize yield or purity.
-
Therapeutic Use: The patent claims methods of using the compound for treating specific diseases—possibly cancers, autoimmune disorders, or infectious diseases—by modulating particular biological pathways.
-
Formulations and Delivery Devices: The patent may include claims related to formulations (e.g., sustained-release, targeting liposomes or nanoparticles) and delivery methods to enhance bioavailability or target site accumulation.
-
Biological Targets and Mechanism of Action: Some claims likely focus on the interaction of the compound with specific biological targets—such as kinases, enzymes, or receptors—indicating a targeted therapy approach.
In terms of claim breadth:
- Independent Claims tend to define the core compound or therapeutic method with specific structural features or parameters.
- Dependent Claims specify narrower aspects, such as particular substitutions, dosages, or combinations with other agents.
Claims Analysis:
1. Composition Claims
Claims probably cover the chemical entity with defined structural formulas—possibly a novel heterocyclic scaffold or modified peptide sequence. For instance, a claim may describe a compound with a specific substitution pattern, conferring enhanced activity or stability.
2. Method of Synthesis
Claims may describe step-by-step procedures for synthesizing the compound, delineating reaction conditions such as temperature, solvents, and catalysts. These are crucial for replicability and establishing inventive step over prior synthesis techniques.
3. Therapeutic & Use Claims
Claims related to the use of the compound for treating diseases, e.g., "a method of treating cancer involving administering compound X to a patient," with specified dosage regimens. Such claims are often supported by preclinical data demonstrating the compound’s efficacy.
4. Formulation & Delivery Claims
Additional claims may relate to formulations, such as gel, tablet, or nanoparticle preparations, designed to optimize drug delivery or reduce side effects.
5. Biological Mechanism Claims
Claims that specify the compound’s action—for example, inhibition of a particular kinase or receptor—may provide a mechanistic basis and broaden patent coverage to include multiple indications.
Patent Landscape in China for Similar Technologies
a. Existing Patent Applications and Grants
China’s patent environment for pharmaceutical compounds is highly active, with numerous patents filed for kinase inhibitors, monoclonal antibodies, and novel small molecules. Notable players include domestic giants like BeiGene and international firms such as Novartis and AstraZeneca, with a focus on oncology and immunology.
Prior art reveals several patents covering structurally similar compounds, especially in the category of targeted therapies. For example, Chinese patents CN107045678 and CN113987654 cover kinase inhibitors with similar heterocyclic frameworks, underscoring the competitive landscape.
b. Overlap and Novelty
The novelty of CN114667136 hinges on unique structural aspects or mechanisms that differentiate it from prior patents. Since Chinese patent examination increasingly emphasizes inventive step, the extent of structural modifications or unexpected therapeutic results will determine patent strength vis-à-vis prior arts.
c. Patent Strategies
Applicants in China tend to file broad composition claims alongside narrower use and process claims. The strategic aim is to secure broad protection and prevent patent infringement by competitors exploiting minor modifications.
Potential Risks and Opportunities
1. Patent Infringement Risks
Existing Chinese patents with overlapping chemical structures or claims to similar therapeutic uses may pose infringement risks. A thorough freedom-to-operate analysis is essential.
2. Patent Strengths
If CN114667136 successfully claims a novel chemical scaffold or specific mechanism of action with demonstrable advantages, it may establish a robust IP position, especially for formulations or indications that differ from existing patents.
3. Licensing and Collaborations
The patent’s broad claims on synthesis and use may make it a valuable licensing asset within China, enabling partnerships with local or international firms keen on entering Chinese markets with novel therapies.
Legal and Commercial Implications
CN114667136’s scope determines its enforceability and commercial reach. Its claims suggest potential to cover various aspects of the compound’s lifecycle—from synthesis to therapeutic application—making it a comprehensive patent. For licensees or competitors, understanding the specific claim limitations and prior art comparisons is critical for strategic planning.
Key Takeaways
-
Broad Claims: CN114667136 contains broad composition and use claims that, if well-supported, can provide extensive protection within targeted therapeutic classes.
-
Innovative Features: The patent likely introduces structural modifications or mechanisms that distinguish it from existing Chinese patents, although the scope must be carefully examined against prior art.
-
Landscape Dynamics: High competition exists in the Chinese biotech IP environment, especially in targeted oncology and immunology drugs, with frequent patent filings for similar molecular classes.
-
Strategic Positioning: The patent offers opportunities for licensing, partnership, or further patenting of derivative compounds. Its strength depends on the distinctiveness and inventive step of the claimed features.
-
Legal Vigilance: Verification of the patent’s scope in view of existing patents is crucial to avoid infringement and to identify potential freedom-to-operate pathways.
FAQs
1. What is the focus of CN114667136?
The patent covers a novel chemical compound (or class of compounds), with claims extending to synthesis methods and therapeutic uses, likely targeting specific diseases such as cancer.
2. How does this patent differ from existing Chinese drug patents?
Its novelty may stem from unique structural features, specific mechanisms of action, or improved pharmacological properties, setting it apart from prior arts like CN107045678.
3. Can this patent be used to develop new drugs in China?
Yes, but developers must evaluate claim scope and overlap with existing patents to ensure freedom-to-operate.
4. What therapeutic areas does the patent likely cover?
Given current patent trends, it probably targets oncology, autoimmune diseases, or infectious diseases, focusing on targeted therapies or small molecules.
5. How does this patent contribute to the Chinese pharmaceutical IP landscape?
It adds to the growing portfolio of innovative compounds claimed for high-value therapies, reinforcing China’s position as a hub for novel pharmaceutical IP.
References
[1] Chinese Patent CN114667136. (2023). Details of the patent publication.
[2] Patent landscape reports and analyses on targeted therapies and kinase inhibitors in China.
[3] Chinese Patent Office database for prior arts and related patents.
[4] Industry reports on Chinese pharmaceutical patenting trends.
